



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Roberts, SK;Majeed, A;Glenister, K;Magliano, D;Lubel, JS;Bourke, L;Simmons, D;Kemp, WW

Title:

Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study

Date:

2021-07-01

Citation:

Roberts, S. K., Majeed, A., Glenister, K., Magliano, D., Lubel, J. S., Bourke, L., Simmons, D. & Kemp, W. W. (2021). Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. *Medical Journal of Australia*, 215 (2), pp.77-82. <https://doi.org/10.5694/mja2.51096>.

Persistent Link:

<https://hdl.handle.net/11343/298584>

PROF. STUART KEITH ROBERTS (Orcid ID : 0000-0002-9015-7997)

Article type : Original Article

Article begins on page three of this document.

Title	Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study
--------------	--

Authors:

	Title	First name	Mid initials	Last name	Postnom (eg, PhD)	Position1	Address1	Position2	Address2	Tel	Email
1	Prof.	Stuart	K	Roberts	MBBS, MD, MPH, FRACP, FAASLD	Director, Hepatology	1	Clinical Professor	2		S.Roberts@alfred.org.au
2	Dr.	Ammar		Majeed			1		2		a.majeed@alfred.org.au
3	Dr.	Kristen		Glenister	BSc. (Hons) PhD.	Research Fellow	3				kristen.glenister@unimelb.edu.au
4	Prof.	Dianna		Magliano	BAppSci(Hons), MPH, PHD	Laboratory Head	4				Dianna.Magliano@baker.edu.au
5	Assoc. Prof.	John	S	Lubel	MBBS, BDS, FDS RCS, MRCP, FRACP PhD	Consultant Gastroenterologist	1	Associate Professor	2		johnlubel@icloud.com
6	Prof.	Lisa		Bourke	PhD	Director UDRH	3			03 5823 4519	bourke@unimelb.edu.au
7	Prof.	David		Simmons		Professor of Medicine	5				Da.Simmons@westernsydney.edu.au
8	Dr.	William	W	Kemp	MBBS, FRACP	Gastroenterologist	1		2	03 9276 2000 / 9529 7377 / 9781 4434	w.kemp@alfred.org.au

Number of corresponding author:	1
Number of alternative corresponding author:	

Addresses:

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/MJA2.51096](https://doi.org/10.1002/MJA2.51096)

	Institution	Postal address	City	State	Post Code	Nation
1	Alfred Health	55 Commercial Road	Melbourne	VIC	3181	
2	Monash University	55 Commercial Rd	Melbourne	VIC	3004	
3	University of Melbourne	49 Graham Street	Shepparton	VIC	3632	
4	Baker IDI Heart and Diabetes Institute	Level 4, 99 Commercial Road	Melbourne	VIC	3004	
5	Macarthur Clinical School, Western Sydney University	Narellan Road & Gilchrist Drive	Sydney	NSW	2560	

Postal address of first corresponding author (if different from the institutional address given above)	
--	--

Primary Keywords [Office use only]	Digestive system diseases; Environment and public health; Nutritional and metabolic diseases
Secondary keywords [Office use only]	Liver diseases; Population health; Metabolic diseases; Obesity; Epidemiology; Risk factors
Notes:	

Article details (press ctrl – 9 to enter details):

Article type	Research
Blurb	The high rate and its association with metabolic risk factors and markers of liver injury have significant public health implications
Pullquote	

Office use

<i>Ms. Number</i>	mja20.01765.R2
<i>Medical editor</i>	Aajuli Shukla
<i>Medical editor email</i>	ashukla@mja.com.au
<i>Structural editor</i>	Paul Foley
<i>Structural editor email</i>	pfoley@mja.com.au
<i>Section/Category</i>	Research
<i>Strapheading</i>	Research
<i>Substrap</i>	

Elsevier – file data:

Filename for copyediting	rob_mja20.01765_ms.docx
Accompanying graphics	rob_mja20.01765_gr2.eps; rob_mja20.01765_gr2.jpg
Stock images	None
Appendices	rob_mja2.00000-sup-0001-supinfo Title: Supplementary methods and results

Office use – history:

Event	Date
Original submission received	25/09/2020

Event	Date
Accept	15/02/2021

Proof sent to author	
Proof returned by author	
Published (date format xx/xx/xx)	19/07/21
Issue	2
Vol	215
DOI	10.5694/mja2 0.01765
Journal	The Medical Journal of Australia
Original article DOI (for response)	

Author Manuscript

Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study

Abstract

Objectives: To investigate the prevalence of non-alcoholic fatty liver disease (NAFLD) and its risk factors in regional Victoria.

Design: Prospective cross-sectional observational study (sub-study to CrossRoads II health study in Shepparton and Mooroopna).

Setting: Four towns (populations, 6300–49 800) in the Goulburn Valley of Victoria.

Participants: Randomly selected from households selected from residential address lists provided by local government organisations for participation in the CrossRoads II study.

Main outcome measures: Age- and sex-adjusted estimates of NAFLD prevalence, defined by a fatty liver index score of 60 or more in people without excessive alcohol intake or viral hepatitis.

Results: A total of 705 invited adults completed all required clinical, laboratory and questionnaire evaluations of alcohol use for inclusion in our analysis (participation rate, 37%); 392 were women (56%), and their mean age was 59.1 years (SD, 16.1 years). Of the 705 participants, 274 met the fatty liver index criterion for NAFLD (crude prevalence, 38.9%; age- and sex-standardised prevalence, 35.7%). The mean age of participants with NAFLD (61 years; SD, 15 years) was higher than for those without NAFLD (58 years; SD, 16 years); a larger proportion of people with NAFLD were men (50% v 41%). Metabolic risk factors more frequent among participants with NAFLD included obesity (69% v 15%), hypertension (66% v 48%), diabetes (19% v 8%), and dyslipidaemia (63% v 33%). Mean serum alanine aminotransferase levels were higher (29 U/L; SD, 17 U/L v 24 U/L; SD, 14 U/L) and mean median liver stiffness greater (6.5 kPa; SD, 5.6 kPa v 5.3kPa; SD, 2.0 kPa; $p<0.005$) in participants with NAFLD.

Conclusion: The prevalence of NAFLD among adults in regional Victoria is high. Metabolic risk factors are more common among people with NAFLD, as are elevated markers of liver injury.

Summary box

The known: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and a leading cause of cirrhosis and liver cancer. Information on the epidemiology of NAFLD in Australia is limited.

The new: The age- and sex-standardised prevalence of NAFLD in regional Victoria was high (36%). People with NAFLD more frequently had metabolic risk factors, such as obesity and diabetes, than other participants in our survey, and their levels of liver injury markers were higher.

The implications: Our findings have important public health implications with regard to managing the expected increase in NAFLD burden over the next few years, particularly in regional communities.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease around the world, with an estimated prevalence of about 25% in white populations.¹ NAFLD, defined as excessive accumulation of fat in the liver of people without excessive alcohol intake, comprises a spectrum of disease ranging from simple steatosis to non-alcoholic steatohepatitis and liver fibrosis, both of which may progress to cirrhosis and liver-related morbidity and death.² Risk factors for NAFLD include obesity, diabetes, dyslipidaemia, and the metabolic syndrome.¹

In Australia, the prevalence of NAFLD is estimated to be 20–30%, affecting about 5.5 million people.^{3,4} This high prevalence has been attributed to the increasing burden of obesity⁵ and the metabolic syndrome.^{5,6} Further, a recent modelling study has found that the burden of NAFLD-related disease in Australia will increase markedly during the current decade.⁶ However, the exact prevalence of NAFLD in Australia remains unknown, as most estimates have been derived from overseas studies or expert opinion.^{3,4,6}

The fatty liver index, based on simple clinical and laboratory parameters,⁷ provides a validated rapid, reliable method for identifying people with fatty liver.^{8–11} More recently, controlled attenuation parameter (CAP) measurement using vibration controlled transient elastography (VCTE) has proved to be a reliable non-invasive tool for assessing hepatic steatosis in people with NAFLD.^{12–14}

We undertook this study as part of the CrossRoads II study (Health in Shepparton and Mooroopna 2016–2018),¹⁵ with the aim of obtaining high quality NAFLD prevalence and epidemiological data for regional communities in Victoria.

Methods

We undertook a cross-sectional epidemiological study in four towns in the Goulburn Valley, a rural region of Victoria 100–300 km north of Melbourne. It was a sub-study of the CrossRoads II study, the methods for which have been published elsewhere.¹⁵ Briefly, in the CrossRoads II study, a face-to-face survey was administered to 1895 of 3022 households (response rate, 63%) randomly selected from residential address lists provided

by local government organisations in four Goulburn Valley towns (town population range, 6300–49 800 people). Health, health behaviour, and health service information reported in the survey was verified and supplemented in a nested sub-study of randomly selected adult participants in clinics conducted in the four towns during 1 October 2016 – 31 December 2018. One adult participant (18 years old or more) was randomly selected from each participating household to attend the clinic, at which they completed further health questionnaires about diet, exercise, and smoking and alcohol history. Anthropometric measures, blood pressure, and oral glucose tolerance were also assessed, as were biochemical parameters — liver function (alanine aminotransferase [ALT], aspartate aminotransferase [AST], γ -glutamyltransferase [GGT]) and serum lipid levels — and viral hepatitis serology. In addition, VCTE with FibroScan (Echosens) was performed when available.

Definition of non-alcoholic fatty liver disease: the fatty liver index

Fatty liver index score — based on waist circumference, body mass index (BMI), and serum triglyceride and GGT levels — was calculated for each participant.⁷ NAFLD was primarily defined as a fatty liver index score of 60 or more in people without excessive alcohol intake (women, ≥ 20 g/day; men ≥ 30 g/day) or viral hepatitis.^{5–9} Alcohol intake was quantified in an eleven-part questionnaire about the type, frequency, and quantity of alcohol consumed (online [Supporting Information](#), health questionnaire).

Liver stiffness

To determine liver stiffness and CAP, VCTE was performed (FibroScan, models 402 or 530 compact; M or XL probes) by one of three experienced hepatologists (authors WK, AM, SKR). CAP was measured with the FibroScan 530 compact machine when available. CAP assessment by VCTE was not available until 19 May 2018. Reliable readings of median liver stiffness required at least ten valid readings (success rate of 60% or more and a median:interquartile range ratio of 0.3 or less). A FibroScan reading of less than 7.0 kPa was deemed normal; a reading of less than 8 kPa excluded advanced fibrosis.¹³ A CAP reading of 302 dB/m or more in people without excessive alcohol intake was deemed to indicate fatty liver.¹⁴

Definition of metabolic syndrome

Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria.¹⁶ Dyslipidaemia was defined according to standard criteria.¹⁷ Obesity was defined as a BMI of 30 kg/m² or more. Hypertension was defined as systolic blood pressure greater than 130 mmHg, diastolic blood pressure greater than 85 mmHg, or the participant requiring anti-hypertensive treatment. Diabetes was defined by self-report.

Statistical analysis

All collected data, including survey questionnaire responses, anthropometric, blood pressure, and pathology assessments, and FibroScan liver stiffness and CAP measurements were entered into a REDCap database, then transferred to Excel (Microsoft) and Stata 14.1 for analysis.

Continuous variables were assessed for normality and summarised as means with standard deviations (SDs); categorical variables were summarised as frequencies and proportions. Age-adjusted NAFLD prevalence estimates were computed by direct standardisation with age- and sex-based group proportions based on 2016 census data for Shepparton, the largest participating town.¹⁸ The statistical significance of differences between people with or without NAFLD were assessed in *t* tests (continuous variables) or Fisher exact tests (categorical variables); $P < 0.05$ (two-tailed) was deemed statistically significant. Given the high prevalence of NAFLD, the robust Poisson method was used to estimate NAFLD prevalence ratios by key metabolic characteristics, adjusted for age and sex.

Ethics approval

Both the CrossRoads II study and this sub-study were approved by the Goulburn Valley Health Human Research Ethics Committee (reference, 20/16).

Results

Of the 1895 adults randomly selected and invited to participate in our sub-study, 1233 agreed to participate (65%); 747 of the 1233 people attended clinic reviews (61% of agreed participants), of whom 705 completed all clinical, laboratory and questionnaire evaluations of alcohol use and were eligible for inclusion in our analysis (overall participation rate, 37%). Most were ethnically white (655, 93%), Australian-born (597, 85%), and women (392, 56%); their mean age was 59.1 years (SD, 16.1 years). Large proportions of the participants were overweight (276, 39%) or obese (252, 36%), or had other metabolic risk factors, including hypertension (55%), dyslipidaemia (44%), high fasting blood glucose levels (23%), and metabolic syndrome (55%) (Box 1). A larger proportion of the invitees who attended the clinic were men than of those who did not (323 of 722, 45% *v* 186 of 510, 36%) and their mean age was higher (non-attenders: 49.8 years; SD, 19.0 years). The demographic and epidemiologic characteristics of people who attended the clinic were similar for those who did or did not complete the evaluations required for study inclusion (Supporting Information, table).

Prevalence of non-alcoholic fatty liver disease

A total of 274 participants fulfilled our fatty liver index definition of NAFLD, a crude prevalence rate of 38.9% (Box 1, Box 2). The age-standardised rate was 35.2%, the age- and sex-standardised prevalence 35.7%. Crude prevalence rates for the four towns ranged between 35% (Benalla) and 46% (Seymour); the rate for the large regional centre Shepparton/Mooroopna (38%) and the three smaller towns combined (40%) were similar.

The prevalence rate exceeded 40% for both men and women aged 60–69 years or 70–79 years, and for men aged 80–89 years (Box 2).

Of the 74 participants who underwent CAP assessment by VCTE, concordance between CAP and fatty liver index assessment was good for the 69 participants with valid CAP measurements ($r^2 = 0.24$), 22 of whom met the CAP-based criteria for NAFLD (sub-group prevalence, 32%). Were a CAP cut-off of 274 dB/m used (optimising sensitivity rather than diagnostic accuracy¹⁴), 34 participants met the criterion (sub-group prevalence, 49%).

Epidemiology of non-alcoholic fatty liver disease

The mean age of participants with NAFLD (61 years; SD, 15 years) was higher than for those without NAFLD (58 years; SD, 16 years), as was their mean body weight (95 kg; SD, 17 kg v 74 kg; SD, 16 kg); a larger proportion of people with NAFLD were men (50% v 41%). Several metabolic risk factors were more frequent among participants with NAFLD than for those without NAFLD: obesity (69% v 15%), hypertension (66% v 48%), diabetes (19% v 8%), and dyslipidaemia (63% v 33%) (Box 1).

Prevalence of non-alcoholic fatty liver disease, by demographic and metabolic risk factors

The prevalence of NAFLD among men aged 60 years or more was particularly high (96 of 196 participants, 49%). Prevalence was at least 45% in men and women in both age categories (under 60 years, 60 years or more) with major metabolic risk factors (obesity, diabetes, dyslipidaemia, and the metabolic syndrome; Box 3). The prevalence of NAFLD was higher in overweight (age- and sex-adjusted prevalence ratio [aPR], 12; 95% CI, 4.6–33) and obese people (aPR, 32; 95% CI, 12–86) than in people with BMI values below 25 kg/m² (Box 4).

Measures of liver disease severity

Mean serum ALT levels were higher for NAFLD participants (29 U/L; SD, 17 U/L) than for those without NAFLD (24 U/L; SD, 14 U/L); the proportion with values greater than 150% of the upper limit of normal was similarly higher (18% v 10%). Liver stiffness was assessed by VCTE in 388 of 705 participants (55%), of whom 375 had valid readings. The mean value was higher in the 143 participants with NAFLD (6.5 kPa; SD, 5.6 kPa) than in the 232 participants without NAFLD (5.3 kPa; SD, 2.0 kPa). The liver stiffness measurement was 8 kPa or more (ie, advanced fibrosis could not be excluded) for 18 participants with NAFLD (13%). In the 69 participants with valid CAP measurements, mean values were higher for the 22 with NAFLD (305 dB/m; SD, 63 dB/m) than for the 47 without NAFLD (256 dB/m; SD, 52 dB/m) (Box 5).

Discussion

NAFLD is emerging as a serious health problem in Australia because of its high prevalence and potential to cause cirrhosis and liver cancer, but local high quality

epidemiologic data on NAFLD are limited.³ We therefore undertook a population-based study, using the fatty liver index as a marker, to evaluate the prevalence and epidemiology of NAFLD in four towns in the Goulburn Valley of Victoria. Our main findings were that the age- and sex-standardised prevalence of NAFLD among adults was high, and that metabolic risk factors and markers of liver injury were more frequent among people with NAFLD.

The fatty liver index is an accepted and validated tool for detecting NAFLD in large epidemiologic studies,¹⁰ particularly in predominantly white populations.^{8,9} Several studies have reported good concordance of fatty liver index scores with hepatic ultrasound for detecting hepatic steatosis in white people.¹⁰ In our study, we used the fatty liver index to estimate crude and age- and sex-adjusted prevalence rates of NAFLD in regional Victoria, and found them to be high (crude, 39%; adjusted, 36%), with rates exceeding 45% in people aged 60 years or more, and in people with metabolic risk factors. Our findings are similar to the 32.5% rate for a large multi-ethnic United States sample similarly assessed with the fatty liver index,¹¹ and higher than the 10–14% reported for the general Australian population in studies that used elevated ALT levels as the marker of NAFLD.^{6,19}

Another important finding was that prevalence of several metabolic risk factors, including obesity, elevated fasting blood glucose levels, hypertension, dyslipidaemia, and metabolic syndrome was high in our rural sample, as we also found in our earlier study.^{20,21} The prevalence of metabolic risk factors was particularly high in participants with NAFLD, including obesity (75%), diabetes (19%), hypertension (66%), and dyslipidaemia (63%). Our data not only provide strong justification for the proposed change in nomenclature from NAFLD to metabolic-associated fatty liver disease (MAFLD),²² but also the inclusion of obesity as a diagnostic criterion for MAFLD.²³ Further, while the MAFLD definition does not include fatty liver index as a marker of hepatic steatosis,²³ 333 of 705 clinic attenders in our study (47%) would have met the diagnostic criteria for MAFLD according to their fatty liver index scores, all but seven of whom were overweight or obese.

One unique aspect of our study was that we used VCTE to assess the prevalence and severity of asymptomatic liver disease in a substantial number of participants attending the regional clinics. We found that mean median liver stiffness was greater for participants with NAFLD than for those without NAFLD, and that readings for about one in eight participants with NAFLD were consistent with advanced liver fibrosis. Similarly, serum ALT levels were higher in participants with NAFLD. Given the relationship between elevated ALT levels and increased all-cause mortality in the general population²⁴ and in older people,²⁵ as well as the high prevalence of NAFLD and its association with several metabolic risk factors, our findings confirm that NAFLD may become a significant public health problem during the next ten years.⁶

Strengths and limitations

Our study was the first to evaluate the epidemiology of NAFLD in Australian adults at the population level using an established marker for fatty liver, and employing validated methodology, including random participant selection and comprehensive data collection from almost all clinic attenders.¹⁵ However, the study was set in a single area of regional Victoria, with a predominantly white population of limited ethnic diversity. As about 30% of the Australian population (about 7 million people) live in rural and remote areas,²⁶ our findings may be relevant to white residents in these regions, even if they are not generalisable to metropolitan populations with more diverse communities. Secondly, although the fatty liver index is accepted for evaluating NAFLD at the population level and has been validated in a population of older white people,⁸ it underestimates the risk of lean non-alcoholic steatohepatitis in people with normal body weight.¹⁰ However, our CAP data supported our fatty liver index-based findings; NAFLD prevalence estimated using CAP was 32% or 49%, depending on the cut-off applied, and the mean CAP reading for participants with NAFLD was higher than for those without NAFLD. Finally, although our reported prevalence rate was age- and sex-standardised and the final participation rate was reasonable (37%), selection bias was possible, as people concerned about their own health, including older people and women, may have been more likely to accept invitations to health check-ups.

Conclusion

Our population-based epidemiologic study of adults in regional Victoria was the first to assess the burden of NAFLD in Australia. The high prevalence rate, strong association with metabolic risk factors, and high levels of non-invasive markers of liver injury in people with NAFLD have significant public health implications for the coming decade.

Acknowledgements: The investigation was supported by a National Health and Medical Research Council partnership grant (APP 1113850). We thank Dunya (Dee) Tomic, medical student at Monash University, for helping collate the initial dataset.

Competing interests: No relevant disclosures.

Received 25 September 2020, accepted 15 February 2021

Author details

Stuart K Roberts^{1,2}

Ammar Majeed^{1,2}

Kristen Glenister³

Dianna Magliano⁴

John S Lubel^{1,2}

Lisa Bourke³

David Simmons⁵

William W Kemp^{1,2}

- 1 Alfred Health, Melbourne, VIC.
- 2 Monash University, Melbourne, VIC.
- 3 University of Melbourne, Shepparton, VIC.
- 4 Baker IDI Heart and Diabetes Institute, Melbourne, VIC.
- 5 Macarthur Clinical School, Western Sydney University, Sydney, NSW.

S.Roberts@alfred.org.au

doi: 10.5694/mja20.01765

See Editorial (xxxx)

References

- 1 Younossi ZM, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018; 15: 11-20.
- 2 Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 2015; 13: 643-654.
- 3 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia. *J Gastroenterol Hepatol* 2018; 33 (Suppl 1): 1-11.
- 4 Deloitte Access Economics. The economic cost and health burden of liver disease in Australia. The Gastroenterological Society of Australia/Australian Liver Association. Jan 2013. https://www.gesa.org.au/public/13/files/Education%20%26%20Resources/Clinical%20Practice%20Resources/Cost%20of%20Liver%20Disease/Cost_of_liver_Disease.pdf (viewed July 2020).
- 5 Australian Institute of Health and Welfare. A picture of overweight and obesity in Australia (Cat. no. PHE 216). Nov 2017. <https://www.aihw.gov.au/reports/overweight-obesity/a-picture-of-overweight-and-obesity-in-australia/summary> (viewed May 2021).
- 6 Adams LA, Roberts SK, Strasser SI, et al. Nonalcoholic fatty liver disease burden: Australia, 2019-30. *J Gastroenterol Hepatol* 2020; 35(9):1628-1635.
- 7 Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterology* 2006; 6: 33.
- 8 Koehler EM, Schouten JNL, Hansen BE, et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. *Clin Gastroenterol Hepatol* 2013; 11: 1201-1212.
- 9 Meffert PJ, Baumeister SE, Lerch MM, et al. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. *Am J Gastroenterol* 2014; 109: 1404-1414.
- 10 Vanni E, Bugianesi E. Utility and pitfalls of fatty liver index in epidemiologic studies for the diagnosis of NAFLD. *Aliment Pharmacol Ther* 2015; 41: 406-407.
- 11 Le MH, Yeo YH, Cheung R, et al. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. *J Intern Med* 2020; 287: 711-722.
- 12 Carvalhana S, Leitão J, Alves AC, et al. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. *Liver Int* 2014; 34: e111-e117.
- 13 Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2019; 156: 1264-1281.
- 14 Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology* 2019; 156: 1717-1730.
- 15 Glenister KM, Bourke L, Bolitho L, et al. Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methods. *BMC Public Health* 2018; 18: 670.
- 16 Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Circulation* 2005; 112: 2735-2752.
- 17 Fodor G. Primary prevention of CVD: treating dyslipidaemia. *BMJ Clin Evid* 2010; 2010:0215.
- 18 Australian Bureau of Statistics. 2016 Census QuickStats: Shepparton. Updated 30 Oct 2020. https://quickstats.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/216 (viewed Oct 2020).
- 19 Mahady SE, Gale J, Macaskill P, et al. Prevalence of elevated alanine transaminase in Australia and its

- relationship to metabolic risk factors: a cross-sectional study of 9447 people. *J Gastroenterol Hepatol* 2017; 32: 169-176.
- 20 Devers MC, Campbell S, Shaw J, et al. Should liver function tests be included in definitions of the metabolic syndrome? Evidence from association between liver function tests, components of the metabolic syndrome, and prevalent cardiovascular disease. *Diab Med* 2008; 25: 523-529.
- 21 Devers MC, Campbell S, Simmons D. Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease, *BMJ Open Diab Res Care* 2016; 4: e000195.
- 22 Eslam M, Sanyal A, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology* 2020; 158: 1999-2014.
- 23 Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; 73: 202-209.
- 24 Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. *Int J Epidemiol* 2014; 43: 187–201.
- 25 Mahady SE, Wong G, Turner RM, et al. Elevated liver enzymes and mortality in older individuals a prospective cohort study. *J Clin Gastroenterol* 2017; 51: 439–445.
- 26 Australian Institute of Health and Welfare. Australia's health 2018 (AIHW cat no. AUS 221; Australia's health series no. 16). June 2018. <https://www.aihw.gov.au/getmedia/8de32746-bc94-49e7-b803-0a7fac42b874/aihw-aus-221-chapter-1-2.pdf.aspx> (viewed Feb 2021).

Box 1. Demographic, clinical, and laboratory characteristics of the 705 participants, by non-alcoholic fatty liver disease (NAFLD) status*

Characteristic	All participants	With NAFLD	Without NAFLD	<i>P</i>
Number of participants	705	274	431	
Sex (men)	313 (44.4%)	136 (49.6%)	177 (41.1%)	0.029
Age (years), mean (SD)	59.1 (16.1)	61.2 (15.4)	57.7 (16.4)	0.005
Born in Australia	597 (84.8%)	232 (84.7%)	365 (84.9%)	1.0
Ethnic background				0.78
White	655 (92.9%)	257 (93.8%)	398 (92.3%)	
Asian	30 (4.3%)	9 (3%)	21 (4.9%)	
Aboriginal/Torres Strait Islander	6 (0.9%)	2 (0.7%)	4 (0.9%)	
Other	14 (2.0%)	6 (2%)	8 (2%)	
Regional town				0.33
Shepparton/Mooroopna	331 (46.9%)	125 (45.6%)	206 (47.8%)	
Benalla	150 (21.3%)	53 (16%)	97 (22%)	
Cobram	109 (15.5%)	43 (16%)	66 (15%)	
Seymour	115 (16.3%)	53 (19%)	62 (14%)	
Weight (kg), mean (SD)	82.2 (19.1)	95.0 (17.3)	74.0 (15.5)	< 0.001
Body mass index (kg/m ²), mean (SD)	29.7 (19.6)	33.5 (5.9)	27.3 (24.4)	< 0.001
Body mass index, category				< 0.001
Underweight/normal (< 25 kg/m ²)	177 (25.1%)	4 (2%)	173 (40.1%)	
Overweight (25– < 30 kg/m ²)	276 (39.2%)	82 (30%)	194 (45.0%)	
Obese (≥ 30 kg/m ²)	252 (35.7%)	188 (68.6%)	64 (15%)	
Waist circumference (cm), mean (SD)	99 (15)	110 (12)	91 (12)	< 0.001
Large waist circumference [†]	412 (58.4%)	240 (87.6%)	172 (39.9%)	< 0.001
Hypertension	385 (54.9%)	180 (65.9%)	205 (47.9%)	< 0.001
Dyslipidaemia	311 (44.1%)	172 (62.8%)	139 (33.3%)	< 0.001
Diabetes	87 (12%)	53 (19%)	34 (7.9%)	< 0.001
Excessive alcohol intake [‡]	99 (14%)	0	99 (23%)	—
Metabolic syndrome	204 (29.7%)	142 (52.6%)	62 (15%)	< 0.001
Laboratory values				
γ-Glutamyltransferase (U/L), mean (SD)	33 (39)	40 (42)	28 (36)	< 0.001
Fasting glucose ≥ 5.6 mmol/L	164 (23.3%)	100 (37%)	64 (14%)	< 0.001
Glycated haemoglobin, mean (SD)	5.5 (0.7)	5.7 (0.9)	5.3 (0.6)	< 0.001
Total cholesterol (mmol/L), mean (SD)	4.9 (1.0)	4.8 (1.0)	5.0 (1.0)	0.12
LDL cholesterol (mmol/L), mean (SD)	2.8 (0.9)	2.8 (0.9)	2.9 (0.9)	0.13
HDL cholesterol (mmol/L), mean (SD)	1.4 (0.4)	1.2 (0.3)	1.6 (0.4)	< 0.001

Low HDL cholesterol [§]	184 (26.1%)	121 (44.2%)	63 (15%)	< 0.001
Triglycerides \geq 1.7 mmol/L	192 (27.2%)	121 (44.1%)	71 (16%)	< 0.001

HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviation.


* Fatty liver index score of 60 or more in people without excessive alcohol intake or viral hepatitis.

† Women, > 88 cm; men, > 102 cm.

‡ Women, \geq 20 g/day; men, \geq 30 g/day.

§ Women, < 1.3 mmol/L; men, < 1.04 mmol/L.

Box 2. Prevalence of non-alcoholic fatty liver disease in the 705 participants, by age and sex



Numbers of people, by age and sex: 18–29 years (15 men, 22 women), 30–39 years (31 men, 46 women), 40–49 years (30 men, 39 women), 50–59 years (41 men, 81 women), 60–69 years (88 men, 98 women), 70–79 years (83 men, 82 women), and 80–89 years (25 men, 24 women); all ages: 313 men, 392 women.

Box 3. Prevalence of non-alcoholic fatty liver disease (NAFLD) by age, sex, and metabolic risk factors

Characteristic	Men		Women		All participants			
	< 60 years	≥ 60 years	< 60 years	≥ 60 years	< 60 years	Proportion (95% CI)	≥ 60 years	Proportion (95% CI)
Participants	117	196	188	204	305		400	
Participants with NAFLD	40 (34%)	96 (49%)	62 (33%)	76 (37%)	102	33% (28–39%)	172	43% (38–48%)
Body mass index								
< 25 kg/m ²	0/28	3/33 (3%)	1/59 (2%)	0/57	1/87	1% (0–6%)	3/90	3% (0.7–9%)
25–29 kg/m ²	16/55 (29%)	47/102 (36%)	6/54 (11%)	13/65 (20%)	22/109	20% (13–29%)	60/167	36% (29–44%)
≥ 30 kg/m ²	24/34 (71%)	46/61(75%)	55/75 (73%)	63/82 (77%)	79/109	73% (63–81%)	109/143	76% (68–83%)
Diabetes								
Yes	10/12 (83%)	20/34 (59%)	6/11 (55%)	17/30 (57%)	16/23	70% (47–87%)	37/64	58% (45–70%)
No	30/105 (29%)	76/162 (47%)	56/177 (32%)	59/174 (34%)	86/282	30% (25–36%)	135/336	40% (35–46%)
Hypertension								
Yes	28/62 (45%)	73/137 (53%)	31/66 (47%)	48/120 (40%)	59/128	46% (37–55%)	121/257	47% (41–53%)
No	12/55 (22%)	23/58 (40%)	30/119 (25%)	28/84 (33%)	42/174	24% (18–31%)	51/142	36% (28–44%)
Dyslipidaemia								
Yes	31/54 (57%)	51/88 (58%)	42/83 (51%)	48/86 (56%)	73/137	53% (45–62%)	99/174	57% (49–64%)
No	9/63 (14%)	45/108 (42%)	20/105 (19%)	28/118 (24%)	29/168	17% (12–24%)	73/226	32% (26–39%)
Metabolic syndrome								
Yes	22/28 (79%)	47/70 (67%)	28/40 (70%)	45/66 (67%)	50/68	74% (61–83%)	92/136	68% (59–75%)
No	17/86 (20%)	46/118 (39%)	34/144 (24%)	31/136 (39%)	51/230	21% (16–27%)	77/254	30% (25–36%)

CI = confidence interval.

Box 4. Age- and sex-adjusted non-alcoholic fatty liver disease prevalence ratios, by metabolic risk factor

Characteristic	Adjusted prevalence ratio (95% CI)
Body mass index	
< 25 kg/m ²	1
25–29 kg/m ²	12 (4.6–33)
≥ 30 kg/m ²	32 (12–86)
Diabetes	
Yes	1
No	1.6 (1.3–2.0)
Hypertension	
Yes	1
No	1.5 (1.2–1.8)
Dyslipidaemia	
Yes	1
No	2.1 (1.8–2.6)
Metabolic syndrome	
Yes	1
No	2.6 (2.2–3.1)

CI = confidence interval.

Author Manuscript

Box 5. Non-invasive markers of liver disease severity in patients with and without non-alcoholic fatty liver disease (NAFLD)

Characteristic	Participants with NAFLD			Participants without NAFLD			P
	All	Men	Women	All	Men	Women	
All participants	274	136	138	431	177	254	
Alanine aminotransferase (U/L), mean (SD)	29 (17)	32 (14)	27 (20)	24 (14)	28 (13)	21 (14)	< 0.001
> 1.5 × upper limit of normal*	48 (18%)	19 (14%)	29 (21%)	44 (10%)	16 (9%)	28 (11%)	0.006
Aspartate aminotransferase (U/L), mean (SD)	26 (9)	28 (7)	25 (10)	26 (9)	28 (9)	24 (9)	0.68
Median liver stiffness measurement (kPa), mean (SD)	6.5 (5.6)	6.1 (4.8)	6.9 (6.3)	5.3 (2.0)	5.7 (2.3)	4.9 (1.7)	0.005
< 7 kPa	114/143 (80%)	60/74 (81%)	54/69 (78%)	197/232 (85%)	85/104 (82%)	112/1228 (88%)	0.21
≥ 8 kPa	18/143 (13%)	9/74 (12%)	9/69 (13%)	21/232 (9%)	12/104 (12%)	9/128 (7%)	0.30
Controlled attenuation parameter (dB/m), mean (SD)	305 (63)	323 (52)	282 (69)	256 (52)	263 (65)	250 (42)	0.001
Participants with valid measurements	22	13	9	47	25	22	

* Women, 20 U/L; men, 30 U/L.